Lansoprazole: An overview of clinical experience from 1997 to 1999;Lansoprazolo: Analisi delle esperienze cliniche nel triennio 1997-1999

Recenti Progressi in Medicina

Volumn 91, Issue 4, 2000, Pages 191-210

  Dobrilla, Giorgio ^a,c   Capurso, Lucio ^b  

^a Ospedale Regionale   (Italy)

^b SAN FILIPPO NERI HOSPITAL   (Italy)

^c NONE   (Italy)

Author keywords

Eradicating therapy; Helicobacter pylori; Lansoprazole; NSAIDs; Omeprazole; Peptic ulcer; Ranitidine; Reflux esophagitis

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ANTIBACTERIAL ACTIVITY; BIOEQUIVALENCE; CLINICAL TRIAL; DRUG EFFICACY; DYSPEPSIA; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; REVIEW; ZOLLINGER ELLISON SYNDROME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CLINICAL TRIALS; GASTROESOPHAGEAL REFLUX; HUMANS; OMEPRAZOLE; PEPTIC ULCER; RECURRENCE; ZOLLINGER-ELLISON SYNDROME;

EID: 0034072718     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Garner A, Fadallah H, Parsons ME. 1976 and all that - 20 years of antisecretory therapy. Gut 1996; 39: 784-786.
2. Sontag SJ, Schnell TG, Chejfec G, Kurucar C, Karpf J, Levine G. Lansoprazole heals erosive reflux oesophagitis in patients with Barrett's oesophagus. Aliment Pharmacol Ther 1997; 11: 147-56.
3. Sontag SJ, Kogut DG, Fleischmann R, Campbell DR, Richter J, Robinson M, McFarland M, Sabesin S, Lehman GA, Castel D. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. Am J Gastroenterol 1997; 92: 429-437.
4. Voev A, Stimac D, Vceva A, Rubinic M, Ivandic A, Ivanis N, Horvat D, Volaric M, Karner I. Lansoprazole versus omeprazole in the treatment of reflux esophagitis. Acta Med Croatica 1997; 51: 171-4.
5. Earnest DL, Dorsch E, Jones J, Jennings DE, Greshi-Rose PA. A placebo-controlled dose-ranging study of Lansoprazole in the management of reflux esophagitis. Am J Gastroenterol 1998; 93: 238-243.
6. Pilotto A, Franceschi M, Leandro G, Di Mario F, Valeio G. Comparison of omeprazole, lansoprazole and pantoprazole in the treatment of elderly patient with esophagitis. Gastroenterology 1999; 116: G1242.
7. Cucchiara S, Borelli O, Gaudiello G, Boccia G, Fecarotta S, Spadaro R, Terrin G. Lansoprazole in children with severe gastroensophageal reflux disease: effect on gastric acidity, esophagitis, and clinical outcome.Gastroenterology 1999; 116: G0612.
8. Hatlebakk JG, Berstad A. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Aliment Pharmacol Ther 1997; 11: 365-72.
9. Carling L, Axelsson CK, Forssell H, Stubberöd A, Kraglund K, Bonnevie O, Ekström. Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long term comparative study. Aliment Pharmacol Ther 1998; 12: 985-90.
10. Jaspersen D, Diehl K-L, Schoeppner H, Geyer P, Martens E. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. Aliment Pharmacol Ther 1998; 12: 49-S2.
11. Bardhan KD, Crouch SL. Low dose lansoprazole is significantly superior to omeprazole in the prevention of relapse in patients with mild to moderate reflux oesophagitis. Gut 1999; 44: 113 (abstr).
12. Dekker W, Mulder CJI, Geboes K. Long term therapy with lansoprazole 30 mg in preventing relapse reflux oesophagitis: clinical and histological evolution at 3 years. Gastroenterology 1999; 116: G0633.
13. Hirschowitz BI, Greshi-Rose P, Huang B, Murray S. Lansoprazole is superior to ranitidine in maintenance of healed erosive esophagitis. Gastroenterology 1999; 116: G0816.
14. Russo A, Dattilo M. Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double-blind clinical trial. Ital J Gastroenterol Hepatol 1997; 29: 312-9.
15. Bardhan KD, Crowe J, Thompson RPH, Trewby PN, Keeling PN, Weir D, Crouch SL. Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse. Aliment Pharmacol Ther 1999; 13: 827-32.
16. Dobrilla G, Piazzi L, Fiocca R. Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: a randomized, multicenter, double masked trial. Clin Therapeutics 1999; 21: 1321-1332.
17. Lanza F, Goff J, Silvers D, Winters J, Jhala N, Jennings D, Greski-Rose P. Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group. Dig Dis Sci 1997; 42: 2529-36.
18. Kovacs TO, Campbell D, Haber M, Rose P, Jennings DE, Richter J. Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo in the maintenance of healed gastric ulcer. Dig Dis Sci 1998; 43: 779-85.
19. Parente F, Bargiggia S, Bollani S, Colombo E, Porro GB. Continuous maintenance with low-dose lansoprazole versus Helicobacter pylori eradication in the prevention of duodenal ulcer recurrence. Hepatogastroenterology 1998; 45: 990-3.
20. 2-receptor antagonists. Aliment Pharmacol Ther 1999; 13: 959-967.
21. Caselli M, Trevisani L, Tursi A, Sartori S, Ruina M, Luzzi I, Gaudenzi P, Alvisi V, Gasbarrini G. Short-term low dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1997; 9: 45-8.
22. Chey WD, Fisher L, Elta GH, Barnett JL, Nostrant T, DelValle J, Hasler WL, Scheiman JM. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. Am J Gastroenterol 1997; 92: 1483-6.
23. de Boer WA, Van Etten RJXM, Schade RWB, Ouwehand ME, Schneeberger PM, Van Unnik AJM Tyrgat GNJ. One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 109-12.
24. de Boer SY, Siem TH. Four-day quadruple therapy as a routine treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 1119-21.
25. Lim Ag et al. Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxicillin. Aliment Pharmacol Ther 1997; 11: 537-540.
26. Kihira K, Satoh K, Saifuku K, Taniguchi Y, Takimoto T, Yamamoto H, Ido K, Yoshida Y, Kimura K. Comparison of ranitidine and lansoprazole in short-term low-dose triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 511-4.
27. Takimoto T, Satoh Kiichi, Taniguchi Yushi Saifuku Joji, Kihira Ken, Seki M, Ypshida Y, Ido K, Kimura K. The efficacy and safety of one-week triple therapy with lansoprazole, clarithromycin, and metronidazole for the treatment of Helicobacter pylori infection in Japanese patients. Helicobacter 1997; 2: 86-91.
28. Graham DY, Hoffman J, El-Zimaity HMT, Graham DP, Osato M. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 935-38.
29. Grupta VK, Dhar A, Seinivasan S, Rattan A, Sharma MP. Eradication of H.pylori in a developing country: comparison with lansorpazole versus omeprazole with norfloxacin, in a dual-therapy study. Am J Gastroenterol 1997; 92: 1140-2.
30. Lazzaroni M, Bargiggia S, Porro GB. Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. Am J Gastroenterol 1997; 92: 649-652.
31. Kayser S, Flury R, Zbinden R, Fried M, Wirth HP. Comparative effect of lansoprazole/ amoxicillin with omeprazole/amoxicillin for the eradication of Helicobacter pylori in patients with duodenal ulcer. Schweiz Med Wochenschr 1997; 127: 722-7.
32. Ahuja V, Dhar A, Bal C, Sharma MP. Lansoprazole and secnidazole with clarithromycin, amoxicillin or pefloxacin in the eradication of Helicobacter pylori in developing country. Aliment Pharmacol Ther 1998; 12: 551-5.
33. Battaglia G, Di Mario F, Leandro G, Benvenuti ME, Donisi PM, Vianello F, Dal Bò N, Pasini M, Pasquino M, Vigneri S. Optimal PPI-based triple therapy for the cure of Helicobacter pylori infection: a single center comparison of four 14-day schedules. Helicobacter 1998; 3: 115-9.
34. de Boer WA, Van Etten RJXM, Coremans A, Schneeberger PM. Two-day "weekend" lansoprazole-quadruple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1998; 12: 77-81.
35. Fennerty MB, Kovacs TO, Krause R, Haber M, Weissfeld A, Siepman N, Rose P. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. Arch Intern Med 1998; 158: 1651-6.
36. Georgopoulos S, Artikis V, Papamarkos D, Karatapanis Sav, Giannakidis S, Vretou N, Karatapanis S. Lansoprazole vs ranitidine bismuth citrate (RBC) based short-term triple therapies for Helicobacter pylori eradication: a randomised study. Am J Gastroenterol 1998; 93: 1634 (abstract).
37. Hahm KB, Lee KJ, Kim YS, Kim JH, Cho SW, Yim H, Joo HJ. Augmented eradication rates of Helicobacter pylori by new combination therapy with lansoprazole, amoxicillin, and rebamipide. Dig Dis Sci 1998; 43: 235-40.
38. Harris AW, Misiewicz JJ, Bardhan KD, Levi S, O'-Morain C, Coop BT, Kerr GD, Dixon MF, Langworthy H, Piper D. Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group. Aliment Pharmacol Ther 1998; 12: 741-5.
39. Ikezawa K, Kashimura H, Mahmudul H, Nakahara A, Yanaka A, Matsuzaki Y, Mutoh H, Tanaka N. Miconazole gel increases the cure rate of Helicobacter pylori infection when added to lansoprazole and amoxicillin in a randomized trial. Helicobacter 1998; 3: 120-4.
40. Kato S, Ritsuno H, Ohnuma K, Iinuma K, Sugiyama T, Asaka M. Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children. Helicobacter 1998; 3: 278-82.
41. Korman MG, Bolin TD, Nicholson FB, Engelman JL. Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection. Helicobacter 1998; 3: 202-5.
42. Lamouliatte H, Cayla R, Zerbib F, Forestier S, de Mascarel A, Joubert-Collin M, Mégraud F. Dual therapy using double dose of lansoprazole with amoxycillin versus triple therapy using a double dose of Lansoprazole, Amoxicillin, and Clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study. Am J Gastroenterol 1998; 93: 1531-4.
43. Louw JA, Van Rensburg CJ, Moola S, Kotze D, Marks IN. Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxicillin and clarithromycin. Aliment Pharmacol Ther 1998; 12: 881-5.
44. O'Connor HJ, McLoughlin R, Kelly S, Laundon J, Cunnane K. Lansoprazole triple therapy for Helicobacter pylori- is 5 days enough? Aliment Pharmacol Ther 1998; 12: 273-6.
45. Pohle T, Stoll R, Kirchner T, Keep M, Lehn N, Bock H, Domschke W. Eradication of Helicobacter pylori with lansoprazole, roxithromycin and metronidazole - on open pilot study. Aliment Pharmacol Ther 1998; 12: 1273-8.
46. Perng CL, Kim JG, El-Zimaity HM, Osato MS, Graham DY. One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter poylori infection in peptic ulcer disease in Korea. Dig Dis Sci 1998; 43: 464-7.
47. Scott BB. Bismuth-contaning single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 1998; 12: 277-9.
48. Spadaccini A, De Fanis C, Sciampa G, Russo L, Silla M, Pantaleone U, Di Virgilio M, Pizzicanella G. Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. Aliment Pharmacol Ther 1998; 12: 997-1001.
49. Spinzi GC, Bierti L, Bortoli A, Colombo E, Fertitta AM, Lanzi GL, Venturelli R, Minoli G. Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1998; 12: 433-8.
50. Suzuki J, Mine T, Kobayasi I, Fujita T. Assessment of a new triple agent regimen for the eradication of Helicobacter pylori and the nature of H.pylori resistance to this therapy in Japan. Helicobacter 1998; 3: 59-63.
51. Trevisani L, Sartori S, Galvani F, Ruina M, Caselli M, Verdianelli G, Abbasciano V. Evaluation of a new ultrashort triple therapy for Helicobacter pylori disease. Aliment Pharmacol Ther 1998; 12: 1269-72.
52. Trevisani L, Sartiri S, Caselli M, Ruina M, Verdianelli G, Abbasciano V. A Four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection. Am J Gastroenterol 1998; 93: 390-3.
53. Cammarota G, Papa A, Cianci R, Cannizzaro O, Armuzzi A, Gasbarrini A, Addolorato G, Gasbarrini GB. Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study. Eur J Gastroenterol Hepatol 1999; 11: 247-50.
54. Ducons JA, Santolaria S, Guirao R, Ferrero M, Montoro M, Gomollón F. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxicillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther 1999; 13: 775-80.
55. Grimley CE, Penny A, O'Sullivan M, Shebani M, Lismore JR, Cross R, Illing RC, Loft DE, Nwokolo CU. Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. Aliment Pharmacol Ther 1999; 13: 869-73.
56. Kashimura H, Suzuki K, Hassan M, Ikezawa K, Sawahata T, Watanabe T, Nakahara A, Mutoh H, Tanaka N. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxicillin and clarithromycin increases the cure rate of Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: 483-7.
57. Lam SK, Wong BCY. Prospective double-blind randomized placebo-controlled study comparing two lansoprazole-based triple therapy and one dual therapy for H.pylori-related duodenal ulcer: an Asian multicenter study. J Gastroenterol Hepatol 1999; 14: A5.
58. Mera R, Realpe JL, Bravo LE, DeLany JP, Correa P. Eradication of Helicobacter pylori infection with proton pump based triple therapy in patients in whom bismuth based triple therapy failed. J Clin Gastroenterol 1999; 29: 51-5.
59. Miwa H, Nagahara A, Sato K, Ohkura R, Murai T. Efficacy of 1 week omeprazole or lansoprazole-amoxicillin-clarithromycin therapy for Helicobacter pylori infection in Japanese population. J Gastroenterol Hepatol 1999; 14: 317-21.
60. Nakagawa M, Ooishi M, Yoda Y, Kawamura N, Ooizumi H, Saitou M, Nakagawa S. A comparative study; one week treatment versus two weeks treatment with lansoprazole, amoxicillin and clarithromycin for the eradication of Helicobacter pylori in patient with gastric and duodenal ulcer. Nippon Rinsho 1999; 57: 140-3.
61. Neville PM, Everett S, Langworthy H, Tompkins D, Mapstone NP, Axon ATR, Moayyedi P. The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. Aliment Pharmacol Ther 1999; 13: 497-501.
62. Pilotto A, Fi anceschi M, Leandro G, Bozzola L, Fortunato A, Rassu M, Meli S, Soffiati G, Scagnelli M, Di Mario F, Valerio G. Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylon infection in elderly patients. J Gastroenterol Hepatol 1999; 14: 468-75.
63. Rinaldi V, Zullo A, De Francesco V, Hassan C, Winn S, Stoppino V, Faleo D, Attili AF. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and retreatment with ranitidine bismuth-citrate based triple therapy. Aliment Pharmacol Ther 1999; 12: 1273-8.
64. Schwartz H, Krause R, Sahba B, Haber M et al. Triple versus dual therapy for eradicating helicobacter pylori and preventing ulcer recurrence. A randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/o. Am J Gastroenterol 1999; 94: february 22 (abstract).
65. Sieg A, Sellinger M, Schlauch D, Hörner M, Fuchs W. Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxicillin and clarithromycin to eradicate Helicobacter pylori. Aliment Pharmacol Ther 1999; 13: 865-8.
66. Rose P, Holdings TAP, Deerfield IL, Huang B, Labes A, Park A, Lukasik N, Collis C. Evidence that lansoprazole is effective in preventing NSAID induced ulcers. Gastroenterology 1999; 116: G1293.
67. Matsukawa Y, Tomita Y, Nishinarita S, Horie T, Kato K, Arakawa Y, Ko K, Shimada H, Nakano M, Kitami Y, Kurosaka H. Efficacy of lansoprazole against peptic ulcers induced by non steroidal anti-inflammatory drugs: endoscopie evaluation of ulcer healing. J Int Med Res 1997; 25: 190-5.
68. Agrawal N, Farmington CT, Salfi M, Wruble L, Karvois D, Greski-Rose P, Holdings TAP, Huang B, Park A. Effectiveness of lansoprazole in the healing of NSAID-induced gastric ulcer in patients continuing to take NSAID. Gastroenterology 1998; 114: A94.
69. Pospai D, Cadiot G, Forestier S, Ruszniewski P, et al. Effectiveness and safety of lansoprazole in the treatment of Zollinger-Ellison syndrome. First six months of treatment. Gastroenterol Clin Biol 1998; 22: 801-8.
70. Manzionna G, Pace F, Bianchi Porro G. Efficacy of lansoprazole in the short and long-term treatment of gastroesophageal reflux disease. A systematic overview. Clin Drug Invest 1997; 14: 450-6.
71. Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276: 983-988.
72. Geus WP, Mulder PGH, Gan KH et al. Is twice daily dosing of omeprazole and lansoprazole more effective than once daily dosing? Gastroenterology 1998; 114: A 132 (G0539).
73. Jones R, Crouch SL. Low dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. Aliment Pharmacol Ther 1999; 13: 413-9.
74. Hetzel DJ, Dent J, Reed WD et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903-12.
75. Dobrilla G, Di Fede F. Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview. Clinical Therapeutics 1993; 15: 2-13.
76. Robinson M, Lanza F, Avner D et al. Effective maintenance treatment of reflux esophagitis with low dose lansoprazole. Ann Intern Med 1996; 124: 859-67.
77. 2-RA therapy. Am J Gastroenterol 1996; 91: 1758-65.
78. Gough AL, Long RG, Cooper BT et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux esophagitis. Aliment Pharmacol Ther 1996; 10: 529-39.
79. Yeomans ND, Tulassay Z, Juhasz L et al. A comparison of omeprazole with ranitidine for ulcers associated with non steroidal antinflammatory drugs. New Engl J Med 1998; 338: 719-26.
80. Hawkey CJ, Karasch JA, Szezepanski L et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antinflammatory drugs. New Engl J Med 1998; 338: 727-34.
81. Tomoyuki I, Hiroshi S, Masafumi N et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity agasinst Helicobacter pylori. Antimicrob Agents Chemother 1991; 35: 490-6.
82. Freston JW. Long-term acid control and proton pump inhibitors: interaction and safety issues in perspective. Amer J Gastroenterol 1997; 92: 51S-55S.
83. Andersson T. Pharmacokinetics, metabolism and interaction of acid pump inhibitors. Clin Pharmacokin 1996; 1: 9-28.
84. Bertaccini G, Coruzzi G. Recenti acquisizioni sugli inibitori della pompa protonica. Giornale di Gastroenterologia 1997; 2: 78-82.